The WACC of Allovir Inc (ALVR) is 10.5%.
Range | Selected | |
Cost of equity | 12.60% - 19.30% | 15.95% |
Tax rate | -% - 0.10% | 0.05% |
Cost of debt | 5.00% - 5.00% | 5.00% |
WACC | 8.8% - 12.2% | 10.5% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 1.9 | 2.58 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 12.60% | 19.30% |
Tax rate | -% | 0.10% |
Debt/Equity ratio | 1 | 1 |
Cost of debt | 5.00% | 5.00% |
After-tax WACC | 8.8% | 12.2% |
Selected WACC | 10.5% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for Allovir:
cost_of_equity (15.95%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (1.9) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.